
In today’s briefing:
- Ohayo Japan | S&P Turns Positive for the Year
- Japan Morning Connection: A Flurry of Middle East Dealmaking Drives Tech and Aerospace
- Thematic Report: Will the US MFN Policy for Pharma Impact Indian Pharmaceuticals?
- Biopharma Week in Review – New CBER Head and MFN Headlines Renew Prior Fears
- Furniture/Furnishings Weekly: Trendspotting at IKEA; Time for Some (Tariff Policy) Game Theory
- Sustainable Investing Surveyor Focus on Neste Corporation

Ohayo Japan | S&P Turns Positive for the Year
- US stocks ended mixed Wednesday as tech strength lifted the Nasdaq 0.7% for a sixth straight gain
- Qatar Airways agreed to buy up to 210 Boeing jets worth $96 billion during Trump’s visit, marking a major win for the U.S. plane maker.
- Sony Group forecasts operating profit of 1.28 trillion yen, up 0.3%, for the fiscal year ending March 2026, including a 100 billion yen tariff impact.
Japan Morning Connection: A Flurry of Middle East Dealmaking Drives Tech and Aerospace
- SMCI signs a major $20bn deal with Saudi Arabia’s DataVolt sending server related names higher and should be positive for cooling module supplier Nidec.
- NVDA backed CoreWeave surging as much +10% after hours after numbers and comments from management show a continued demand acceleration for AI infrastructure.
- Boeing signed its largest deal ever with Qatar airlines for up to 210 widebody planes, with GE Aerospace also locking in an order for 400 engines. Positive JP Heavies.
Thematic Report: Will the US MFN Policy for Pharma Impact Indian Pharmaceuticals?
- MFN policy aims to align US drug prices with the lowest prices paid by other developed nations, potentially resulting in significant price reductions.
- Indian pharma players have limited impact, considering only few companies have notable presence in branded markets
- Repercussions for pharma are wider in terms of potential lower R&D spend along with squeezed margins. Though implementation of policy key moniterable
Biopharma Week in Review – New CBER Head and MFN Headlines Renew Prior Fears
- Biopharma was heavily pressured by the appointment of Dr. Vinay Prasad as the FDA’s Center for Biologics Evaluation and Research (CBER) head and concerns over Most-Favored-Nation (MFN) drug pricing.
- The group is again wary of the FDA with Prasad overseeing the regulation of biologics, including vaccines, cell and gene therapies, and blood supply.
- While not anti-vaccine, Prasad’s ideology is closer to RFK Jr. than former CBER head Peter Marks.
Furniture/Furnishings Weekly: Trendspotting at IKEA; Time for Some (Tariff Policy) Game Theory
- De-escalatory movement on tariff policy benefited furniture and furnishings stocks.
- The WTR Commercial/Contract Furniture Index was up 6.5%, the Residential Manufacturers & Suppliers Index was up 2.1%, and the Home Goods Retailers Index was up 2.0%, beating the large- cap indices and the R2K.
- From modernism to hygge and eco-consciousness at IKEA (1). The core business model remains the same (edited vignettes to showcase design and make it easy to outfit an entire house, ready-to-assemble furniture to cut down on logistics and manufacturing costs), but as FT’s architecture and design critic notes, the aesthetics continue to evolve, tracking important social and generational shifts.
Sustainable Investing Surveyor Focus on Neste Corporation
- The WTR Sustainable Index was up 1.3% W/W versus the S&P 500 Index (down 0.5%), the Russell 2000 Index (up 0.1%), and the Nasdaq Index (down 0.2%).
- Energy Technology (12.1% of the index) was up 4.2%, while Industrial Climate and Ag Technology (47.6% of the index) was up 0.5%, ClimateTech Mining was up 1.7%, and Advanced Transportation Solutions (21.5% of the index) was up 1.3%.
- Top 10 Performers: AZRE, AEVA, GCEH, HLGN, ALLIF, PEV, SHLS, EAF, RUN, EVGO